References
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507. DOI:https://doi.org/10.1038/nature12060.
- Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480–496.
- Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453–465.
- Pierson TC, Diamond MS. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams-Wilkins; 2013. p. 747–794.
- Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7–16. DOI:https://doi.org/10.1038/nrmicro2460.
- Clinical management and delivery of clinical services. Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. 2009. Geneva.
- Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158(7):1445–1459.
- Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9. DOI:https://doi.org/10.1086/315215.
- Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis. 1994;19(3):500–512.
- Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
- Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis. 2007;196(3):416–424. DOI:https://doi.org/10.1086/519170.
- Kliks SC, Nimmanitya S, Nisalak A, et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988;38(2):411–419. DOI:https://doi.org/10.4269/ajtmh.1988.38.411.
- Halstead SB. Pathogenesis of dengue: dawn of a new era. F1000Res. 2015;4:532–543.
- Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532–543.
- Deng SQ, Yang X, Wei Y, et al. A review on dengue vaccine development. Vaccines (Basel). 2020;8(1). DOI:https://doi.org/10.3390/vaccines8010063.
- Tully D, Griffiths CL. Dengvaxia: the world’s first vaccine for prevention of secondary dengue. Ther Adv Vaccines Immunother. 2021;9:25151355211015839.
- Watanabe S, Low JG, Vasudevan SG. Preclinical antiviral testing for dengue virus infection in mouse models and its association with clinical studies. ACS Infect Dis. 2018;4(7):1048–1057.
- Chan KW, Watanabe S, Kavishna R, et al. Animal models for studying dengue pathogenesis and therapy. Antiviral Res. 2015;123:5–14.
- Zompi S, Harris E. Animal models of dengue virus infection. Viruses. 2012;4(1):62–82.
- Chen HC, Hofman FM, Kung JT, et al. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J Virol. 2007;81(11):5518–5526. DOI:https://doi.org/10.1128/JVI.02575-06.
- Chen HC, Lai SY, Sung JM, et al. Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol. 2004;73(3):419–431. DOI:https://doi.org/10.1002/jmv.20108.
- Yamanaka A, Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine. 2009;27(28):3735–3743.
- Shresta S, Kyle JL, Robert Beatty P, et al. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology. 2004;319(2):262–273. DOI:https://doi.org/10.1016/j.virol.2003.09.048.
- Huang KJ, Li SJ, Chen SC, et al. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol. 2000;81(Pt 9):2177–2182. DOI:https://doi.org/10.1099/0022-1317-81-9-2177.
- Velandia-Romero ML, Acosta-Losada O, Castellanos JE. In vivo infection by a neuroinvasive neurovirulent dengue virus. J Neurovirol. 2012;18(5):374–387.
- Goncalves D, de Queiroz Prado R, Almeida Xavier E, et al. Immunocompetent mice model for dengue virus infection [corrected]. ScientificWorldJournal. 2012;2012:525947.
- Costa VV, Fagundes CT, Valadao DF, et al. A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-gamma in host resistance to infection. PLoS Negl Trop Dis. 2012;6(5):e1663. DOI:https://doi.org/10.1371/journal.pntd.0001663.
- Wang R, Gao N, Li Y, et al. Cross-protection against four serotypes of dengue virus in mice conferred by a zika dna vaccine. Front Cell Infect Microbiol. 2019;9:147.
- Wang R, Zheng X, Sun J, et al. Vaccination with a single consensus envelope protein ectodomain sequence administered in a heterologous regimen induces tetravalent immune responses and protection against dengue viruses in mice. Front Microbiol. 2019;10:1113.
- Amorim JFS, Azevedo AS, Costa SM, et al. Dengue infection in mice inoculated by the intracerebral route: neuropathological effects and identification of target cells for virus replication. Sci Rep. 2019;9(1):17926. DOI:https://doi.org/10.1038/s41598-019-54474-7.
- Oliveira ER, Amorim JF, Paes MV, et al. Peripheral effects induced in BALB/c mice infected with DENV by the intracerebral route. Virology. 2016;489:95–107.
- Talarico LB, Batalle JP, Byrne AB, et al. The role of heterotypic DENV-specific CD8(+)T Lymphocytes in an immunocompetent mouse model of secondary dengue virus infection. EBioMedicine. 2017;20:202–216.
- Yu JS, Tseng CK, Lin CK, et al. Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses. Antiviral Res. 2017;137:49–57.
- Zou C, Huang C, Zhang J, et al. Virulence difference of five type I dengue viruses and the intrinsic molecular mechanism. PLoS Negl Trop Dis. 2019;13(3):e0007202. DOI:https://doi.org/10.1371/journal.pntd.0007202.
- Chen JM, Fan YC, Lin JW, et al. Bovine lactoferrin inhibits dengue virus infectivity by interacting with heparan sulfate, low-density lipoprotein receptor, and DC-SIGN. Int J Mol Sci. 2017;18(9):1957. DOI:https://doi.org/10.3390/ijms18091957.
- Byrne AB, Garcia AG, Brahamian JM, et al. A murine model of dengue virus infection in suckling C57BL/6 and BALB/c mice. Animal Model Exp Med. 2021;4(1):16–26. DOI:https://doi.org/10.1002/ame2.12145.
- Paes MV, Pinhao AT, Barreto DF, et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology. 2005;338(2):236–246. DOI:https://doi.org/10.1016/j.virol.2005.04.042.
- Abdul Ahmad SA, Palanisamy UD, Khoo JJ, et al. Efficacy of geraniin on dengue virus type-2 infected BALB/c mice. Virol J. 2019;16(1):26. DOI:https://doi.org/10.1186/s12985-019-1127-7.
- Sreekanth GP, Panaampon J, Suttitheptumrong A, et al. Drug repurposing of N-acetyl cysteine as antiviral against dengue virus infection. Antiviral Res. 2019;166:42–55.
- Hu Y, Hu Y, Sun L, et al. Antiviral effects of liposome-encapsulated PolyICLC against Dengue virus in a mouse model. Biochem Biophys Res Commun. 2016;478(2):913–918. DOI:https://doi.org/10.1016/j.bbrc.2016.08.050.
- Yu JS, Wu YH, Tseng CK, et al. Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway. Sci Rep. 7(1): 45171. 2017. . https://doi.org/10.1038/srep45171.
- Wu YH, Tseng CK, Wu HC, et al. Avocado (Persea americana) fruit extract (2R,4R)-1,2,4-trihydroxyheptadec-16-yne inhibits dengue virus replication via upregulation of NF-kappaB-dependent induction of antiviral interferon responses. Sci Rep. 2019;9(1):423. DOI:https://doi.org/10.1038/s41598-018-36714-4.
- Chen RE, Diamond MS. Dengue mouse models for evaluating pathogenesis and countermeasures. Curr Opin Virol. 2020;43:50–58.
- Ashour J, Morrison J, Laurent-Rolle M, et al. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe. 2010;8(5):410–421. DOI:https://doi.org/10.1016/j.chom.2010.10.007.
- Sarathy VV, Infante E, Li L, et al. Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-alpha/beta and IFN-gamma receptors (AG129) and comparison with the DENV-2 AG129 mouse model. J Gen Virol. 2015;96(10):3035–3048. DOI:https://doi.org/10.1099/jgv.0.000246.
- Milligan GN, Sarathy VV, Infante E, et al. A dengue virus type 4 model of disseminated lethal infection in AG129 mice. PLoS One. 2015;10(5):e0125476. DOI:https://doi.org/10.1371/journal.pone.0125476.
- Shresta S, Sharar KL, Prigozhin DM, et al. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol. 2006;80(20):10208–10217. DOI:https://doi.org/10.1128/JVI.00062-06.
- Sarathy VV, White M, Li L, et al. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol. 2015;89(2):1254–1266. DOI:https://doi.org/10.1128/JVI.01320-14.
- Milligan GN, Sarathy VV, White MM, et al. A lethal model of disseminated dengue virus type 1 infection in AG129 mice. J Gen Virol. 2017;98(10):2507–2519. DOI:https://doi.org/10.1099/jgv.0.000923.
- Milligan GN, White M, Zavala D, et al. Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008. Antiviral Res. 2018;154:104–109. DOI:https://doi.org/10.1016/j.antiviral.2018.04.012.
- Tan GK, Ng JK, Lim AH, et al. Subcutaneous infection with non-mouse adapted Dengue virus D2Y98P strain induces systemic vascular leakage in AG129 mice. Ann Acad Med Singap. 2011;40(12):523–532.
- Tan GK, Ng JK, Trasti SL, et al. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis. 2010;4(4):e672. DOI:https://doi.org/10.1371/journal.pntd.0000672.
- Sarathy VV, White M, Li L, et al., Characterization of a murine model of non-lethal, symptomatic dengue virus infection. Sci Rep. 8(1): 4900. 2018. . https://doi.org/10.1038/s41598-018-22618-w.
- Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790. DOI:https://doi.org/10.1371/journal.ppat.1000790.
- Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe. 2010;7(2):128–139.
- Ng JK, Zhang SL, Tan HC, et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog. 2014;10(4):e1004031. DOI:https://doi.org/10.1371/journal.ppat.1004031.
- Schmid MA, Glasner DR, Shah S, et al. Mosquito saliva increases endothelial permeability in the skin, immune cell migration, and dengue pathogenesis during antibody-dependent enhancement. PLoS Pathog. 2016;12(6):e1005676. DOI:https://doi.org/10.1371/journal.ppat.1005676.
- Orozco S, Schmid MA, Parameswaran P, et al. Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol. 2012;93(Pt 10):2152–2157. DOI:https://doi.org/10.1099/vir.0.045088-0.
- Prestwood TR, Morar MM, Zellweger RM, et al. Gamma interferon (IFN-gamma) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-alpha/beta receptor-deficient mice. J Virol. 2012;86(23):12561–12570. DOI:https://doi.org/10.1128/JVI.06743-11.
- Acosta PL, Byrne AB, Hijano DR, et al. Human type i interferon antiviral effects in respiratory and reemerging viral infections. J Immunol Res. 2020;2020:1372494.
- Perry ST, Buck MD, Lada SM, et al. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 2011;7(2):e1001297. DOI:https://doi.org/10.1371/journal.ppat.1001297.
- Christofferson RC, McCracken MK, Johnson AM, et al. Development of a transmission model for dengue virus. Virol J. 2013;10(1):127. DOI:https://doi.org/10.1186/1743-422X-10-127.
- Carlin AF, Plummer EM, Vizcarra EA, et al. An IRF-3-, IRF-5-, and IRF-7-independent pathway of dengue viral resistance utilizes IRF-1 to stimulate Type I and II interferon responses. Cell Rep. 2017;21(6):1600–1612. DOI:https://doi.org/10.1016/j.celrep.2017.10.054.
- Coronel-Ruiz C, Gutierrez-Barbosa H, Medina-Moreno S, et al. Humanized mice in dengue research: a comparison with other mouse models. Vaccines (Basel). 2020; 8(1). DOI: https://doi.org/10.3390/vaccines8010039.
- Wu SJ, Hayes CG, Dubois DR, et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg. 1995;52(5):468–476. DOI:https://doi.org/10.4269/ajtmh.1995.52.468.
- An J, Kimura-Kuroda J, Hirabayashi Y, et al. Development of a novel mouse model for dengue virus infection. Virology. 1999;263(1):70–77. DOI:https://doi.org/10.1006/viro.1999.9887.
- Lin YL, Liao CL, Chen LK, et al. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol. 1998;72(12):9729–9737. DOI:https://doi.org/10.1128/JVI.72.12.9729-9737.1998.
- Blaney JE Jr., Matro JM, Murphy BR, et al. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005;79(9):5516–5528. DOI:https://doi.org/10.1128/JVI.79.9.5516-5528.2005.
- Bente DA, Melkus MW, Garcia JV, et al. Dengue fever in humanized NOD/SCID mice. J Virol. 2005;79(21):13797–13799. DOI:https://doi.org/10.1128/JVI.79.21.13797-13799.2005.
- Mota J, Rico-Hesse R. Dengue virus tropism in humanized mice recapitulates human dengue fever. PLoS One. 2011;6(6):e20762.
- Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol. 2009;83(17):8638–8645.
- Sridharan A, Chen Q, Tang KF, et al. Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice. J Virol. 2013;87(21):11648–11658. DOI:https://doi.org/10.1128/JVI.01156-13.
- Costa VV, Ye W, Chen Q, et al. Dengue virus-infected dendritic cells, but not monocytes, activate natural killer cells through a contact-dependent mechanism involving adhesion molecules. mBio. 2017;8(4). DOI:https://doi.org/10.1128/mBio.00741-17.
- Jaiswal S, Pazoles P, Woda M, et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology. 2012;136(3):334–343. DOI:https://doi.org/10.1111/j.1365-2567.2012.03585.x.
- Jaiswal S, Smith K, Ramirez A, et al. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood). 2015;240(1):67–78. DOI:https://doi.org/10.1177/1535370214546273.
- Akkina R. Humanized mice for studying human immune responses and generating human monoclonal antibodies. Microbiol Spectr. 2014;2(2). DOI:https://doi.org/10.1128/microbiolspec.AID-0003-2012
- Frias-Staheli N, Dorner M, Marukian S, et al. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing. J Virol. 2014;88(4):2205–2218. DOI:https://doi.org/10.1128/JVI.03085-13.
- Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009;106(48):20435–20439. DOI:https://doi.org/10.1073/pnas.0907010106.
- Chen YL, Yin Z, Duraiswamy J, et al. Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother. 2010;54(7):2932–2939. DOI:https://doi.org/10.1128/AAC.00140-10.
- Chen YL, Yin Z, Lakshminarayana SB, et al. Inhibition of dengue virus by an ester prodrug of an adenosine analog. Antimicrob Agents Chemother. 2010;54(8):3255–3261. DOI:https://doi.org/10.1128/AAC.00397-10.
- Zandi K, Bassit L, and Amblard F, et al. Nucleoside analogs with selective antiviral activity against dengue fever and Japanese encephalitis viruses. Antimicrob Agents Chemother. 2019;63(7):e00397–19.
- Lee JC, Tseng CK, Wu YH, et al. Characterization of the activity of 2’-C-methylcytidine against dengue virus replication. Antiviral Res. 2015;116:1–9.
- Nguyen NM, Tran CN, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013;207(9):1442–1450. DOI:https://doi.org/10.1093/infdis/jis470.
- Chen YL, Abdul Ghafar N, Karuna R, et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol. 2014;88(3):1740–1747. DOI:https://doi.org/10.1128/JVI.02841-13.
- Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen. 2007;48(3–4):166–172.
- Byrd CM, Dai D, Grosenbach DW, et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother. 2013;57(1):15–25. DOI:https://doi.org/10.1128/AAC.01429-12.
- Scaturro P, Trist IM, Paul D, et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J Virol. 2014;88(19):11540–11555. DOI:https://doi.org/10.1128/JVI.01745-14.
- Byrd CM, Grosenbach DW, Berhanu A, et al. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother. 2013;57(4):1902–1912. DOI:https://doi.org/10.1128/AAC.02251-12.
- Moquin SA, Simon O, Karuna R, et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci Transl Med. 2021;13(579). DOI:https://doi.org/10.1126/scitranslmed.abb2181.
- Li PC, Jang J, Hsia CY, et al., Small molecules targeting the flavivirus e protein with broad-spectrum activity and antiviral efficacy in vivo. ACS Infect Dis. 5(3): 460–472. 2019. . https://doi.org/10.1021/acsinfecdis.8b00322.
- Modhiran N, Gandhi NS, Wimmer N, et al. Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545. Antiviral Res. 2019;168:121–127.
- Panda K, Alagarasu K, Parashar D. Oligonucleotide-based approaches to inhibit dengue virus replication. Molecules. 2021;26(4):956.
- Stein DA, Huang CY, Silengo S, et al. Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. J Antimicrob Chemother. 2008;62(3):555–565. DOI:https://doi.org/10.1093/jac/dkn221.
- Stein DA, Perry ST, Buck MD, et al. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol. 2011;85(19):10154–10166. DOI:https://doi.org/10.1128/JVI.05298-11.
- Yap SSL, Nguyen-Khuong T, Rudd PM, et al. Dengue virus glycosylation: what do we know? Front Microbiol. 2017;8:1415.
- Hebert DN, Foellmer B, Helenius AJC. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell. 1995;81(3):425–433. DOI:https://doi.org/10.1016/0092-8674(95)90395-x.
- Molinari M, Helenius A. Glycoproteins form mixed disulphides with oxidoreductases during folding in living cells. Nature. 1999;402(6757):90–93.
- Alonzi DS, Scott KA, Dwek RA, et al. Iminosugar antivirals: the therapeutic sweet spot. Biochem Soc Trans. 2017;45(2):571–582. DOI:https://doi.org/10.1042/BST20160182.
- Sadat MA, Moir S, Chun TW, et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med. 2014;370(17):1615–1625. DOI:https://doi.org/10.1056/NEJMoa1302846.
- DeWald L E, Starr C, Butters T, et al. Iminosugars: a host-targeted approach to combat Flaviviridae infections. Antiviral Res. 2020;184:104881.
- Sayce AC, Alonzi DS, Killingbeck SS, et al. Iminosugars inhibit dengue virus production via inhibition of ER alpha-glucosidases–not glycolipid processing enzymes. PLoS Negl Trop Dis. 2016;10(3):e0004524. DOI:https://doi.org/10.1371/journal.pntd.0004524.
- Whitby K, Pierson TC, Geiss B, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol. 2005;79(14):8698–8706. DOI:https://doi.org/10.1128/JVI.79.14.8698-8706.2005.
- Courageot MP, Frenkiel MP, Dos Santos CD, et al. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol. 2000;74(1):564–572. DOI:https://doi.org/10.1128/JVI.74.1.564-572.2000.
- Gu B, Mason P, Wang L, et al. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother. 2007;18(1):49–59. DOI:https://doi.org/10.1177/095632020701800105.
- Lad VJ, Shende VR, and Gupta AK. Effect of catanospermine, 1-deoxynojirimycin or 1-deoxymannojirimycin on biological and functional activities of Japanese encephalitis virus in porcine stable kidney cells. Microbiol Res. 2013;4(1):12–15.
- Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011;92(3):453–460. DOI:https://doi.org/10.1016/j.antiviral.2011.10.002.
- Watanabe S, Chan KW, Dow G, et al. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy. Antiviral Res. 2016;127:10–19.
- Watanabe S, Rathore AP, Sung C, et al., Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 96(1): 32–35. 2012. . https://doi.org/10.1016/j.antiviral.2012.07.008.
- Sung C, Wei Y, Watanabe S, et al. Extended evaluation of virological, immunological and pharmacokinetic endpoints of CELADEN: a randomized, placebo-controlled trial of celgosivir in dengue fever patients. PLoS Negl Trop Dis. 2016;10(8):e0004851. DOI:https://doi.org/10.1371/journal.pntd.0004851.
- Low JG, Sung C, and Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis. 2014;14(8): 706–715.
- Saunier B, Kilker RD Jr., Tkacz JS, et al. Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases. J Biol Chem. 1982;257(23):14155–14161. DOI:https://doi.org/10.1016/S0021-9258(19)45358-1.
- Nishimura Y. gem-Diamine 1-N-iminosugars and related iminosugars, candidate of therapeutic agents for tumor metastasis. Curr Top Med Chem. 2003;3(5):575–591.
- Zitzmann N, Mehta AS, Carrouee S, et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A. 1999;96(21):11878–11882. DOI:https://doi.org/10.1073/pnas.96.21.11878.
- Wu SF, Lee CJ, Liao CL, et al. Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol. 2002;76(8):3596–3604. DOI:https://doi.org/10.1128/JVI.76.8.3596-3604.2002.
- Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007;195(5):665–674. DOI:https://doi.org/10.1086/511310.
- Perry ST, Buck MD, Plummer EM, et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res. 2013;98(1):35–43. DOI:https://doi.org/10.1016/j.antiviral.2013.01.004.
- Bekerman E, Neveu G, and Shulla A, et al., Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338–1352. DOI: https://doi.org/10.1172/JCI89857.
- Pu SY, Xiao F, Schor S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res. 2018;155:67–75.
- Branche E, Tang WW, Viramontes KM, et al. Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection. Antiviral Res. 2018;158:1–7.
- Chuang FK, Liao CL, Hu MK, et al. Antiviral activity of compound L3 against dengue and zika viruses in vitro and in vivo. Int J Mol Sci. 2020;21(11):4050. DOI:https://doi.org/10.3390/ijms21114050.
- Chen HH, Chen CC, Lin YS, et al. AR-12 suppresses dengue virus replication by down-regulation of PI3K/AKT and GRP78. Antiviral Res. 2017;142:158–168.
- Yang CF, Gopula B, Liang JJ, et al. Novel AR-12 derivatives, P12-23 and P12-34, inhibit flavivirus replication by blocking host de novo pyrimidine biosynthesis. Emerg Microbes Infect. 2018;7(1):187. DOI:https://doi.org/10.1038/s41426-018-0191-1.
- Simanjuntak Y, Liang JJ, Lee YL, et al. Repurposing of prochlorperazine for use against dengue virus infection. J Infect Dis. 2015;211(3):394–404. DOI:https://doi.org/10.1093/infdis/jiu377.
- Shen TJ, Hanh VT, Nguyen TQ, et al. Repurposing the antiemetic metoclopramide as an antiviral against dengue virus infection in neuronal cells. Front Cell Infect Microbiol. 2020;10:606743.
- Martinez-Gutierrez M, Correa-Londono LA, Castellanos JE, et al. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS One. 2014;9(2):e87412. DOI:https://doi.org/10.1371/journal.pone.0087412.
- Whitehorn J, Nguyen CVV, Khanh LP, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2016;62(4):468–476. DOI:https://doi.org/10.1093/cid/civ949.
- Soto-Acosta R, Bautista-Carbajal P, Cervantes-Salazar M, et al. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: a potential antiviral target. PLoS Pathog. 2017;13(4):e1006257. DOI:https://doi.org/10.1371/journal.ppat.1006257.
- Farfan-Morales CN, Cordero-Rivera CD, Osuna-Ramos JF, et al. The antiviral effect of metformin on zika and dengue virus infection. Sci Rep. 2021;11(1):8743. DOI:https://doi.org/10.1038/s41598-021-87707-9.
- Htun HL, Yeo TW, Tam CC, et al. Metformin use and severe dengue in diabetic adults. Sci Rep. 2018;8(1):3344. DOI:https://doi.org/10.1038/s41598-018-21612-6.
- Fraser JE, Watanabe S, Wang C, et al. A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. J Infect Dis. 2014;210(11):1780–1791. DOI:https://doi.org/10.1093/infdis/jiu319.
- Carocci M, Hinshaw SM, Rodgers MA, et al. The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother. 2015;59(1):85–95. DOI:https://doi.org/10.1128/AAC.04177-14.
- Choy MM, Zhang SL, Costa VV, et al. Proteasome inhibition suppresses dengue virus egress in antibody dependent infection. PLoS Negl Trop Dis. 2015;9(11):e0004058. DOI:https://doi.org/10.1371/journal.pntd.0004058.